EXO Biologics develops biopharmaceuticals using extracellular vesicles (EVs) to create therapies for rare inflammatory diseases that do not respond to standard treatments. Their proprietary drug loading and delivery platform enhances the therapeutic potential of EVs, providing a safer and more consistent alternative to traditional cell-based therapies.
Funding
$15.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many rare inflammatory diseases do not respond to standard treatments, leaving patients with limited therapeutic options. Traditional cell-based therapies, while promising, can be inconsistent and pose safety risks.
Solution
EXO Biologics develops biopharmaceutical therapies for rare inflammatory diseases by harnessing the potential of extracellular vesicles (EVs), also known as exosomes. Their approach focuses on maximizing the therapeutic potential of exosomes by loading them with specific therapeutic molecules and drugs, using a proprietary drug loading and delivery platform. This platform aims to provide a safer, more consistent, and potentially more cost-effective alternative to traditional cell-based therapeutic approaches. The company leverages a state-of-the-art GMP manufacturing platform to ensure high-quality EVs and exosomes from research to clinical use.
Target Audience
The primary target audience includes patients suffering from rare inflammatory diseases that do not respond to standard treatments, as well as clinicians seeking safer and more effective therapeutic options.
Features
- Proprietary drug loading and delivery platform for enhanced EV therapeutic potential
- Focus on rare inflammatory diseases with high unmet medical needs
- GMP manufacturing platform for high-quality EV production
- Development of therapeutic exosomes as a safer and more consistent alternative to cell-based therapies